Evidence supporting the use of: Immunoglobulin G
For the health condition: Staph Infections

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Immunoglobulin G (IgG), specifically in the form of intravenous immunoglobulin (IVIG), has been investigated as an adjunctive therapy for severe or refractory Staphylococcus infections, particularly in cases involving toxic shock syndrome, sepsis, or in immunocompromised patients. The scientific rationale is that pooled IgG from donors contains a broad spectrum of antibodies, including those capable of neutralizing Staphylococcus aureus toxins such as superantigens and other virulence factors. Some clinical studies and case reports suggest that IVIG can neutralize these toxins, modulate the immune response, and potentially improve outcomes in severe infections where conventional antibiotics alone may be insufficient.

However, the evidence from randomized controlled trials is limited and somewhat conflicting. While some small studies and meta-analyses indicate possible benefits in reducing mortality or severity in toxin-mediated staphylococcal diseases, other trials have not demonstrated significant clinical improvement. Major guidelines do not universally recommend IVIG for routine S. aureus infections, but it may be considered in select, life-threatening cases (such as streptococcal or staphylococcal toxic shock syndrome) where standard therapies have failed. The overall evidence base is moderate (hence, a rating of 3), and use is generally reserved for specific, severe scenarios rather than common staph infections.

More about Immunoglobulin G
More about Staph Infections

Products containing Immunoglobulin G

We currently have no products on Vitabase that contain this ingredient.